Illustrative laboratory work

Management commentary.

Periodic commentary from our Managing Director on the company, its progress and the outlook.

Read the commentary
Management Updated every half-year
Mr. Tejash Hathi, Managing Director of Aptus Pharma

Managing Director’s commentary

H1 FY 2026–27 Published October 2026

H1 FY 2026–27

We are pleased to report a strong H1 performance, with revenue of ₹48.92 crore, EBITDA of ₹7.68 crore, PAT of over ₹5.07 crore, reflecting nearly twofold year-on-year revenue growth.

Aptus Pharma continues its transition from a regional pharmaceutical company towards a broader national presence. As part of our planned expansion, we are targeting 46% geographic coverage across India by March 2027.

Our long-term focus remains on strengthening our product portfolio, expanding our distribution network, developing manufacturing capabilities and exploring opportunities in international markets.

We remain committed to operational excellence, financial discipline, regulatory compliance and sustainable business growth, while pursuing our expansion plans in a phased and responsible manner, subject to market conditions and applicable regulatory requirements.

Mr. Tejash Hathi

Managing Director, Aptus Pharma Limited

Disclaimer on forward-looking statements

This communication is being issued by Aptus Pharma ltd.("the Company") for general information purposes only. The information contained herein is based on management's current expectations and beliefs and is subject to change without notice. Certain statements in this document may be forward-looking in nature and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance, or achievements of the Company to differ materially from those expressed or implied. This document does not constitute or form part of any offer, invitation, or recommendation to purchase, hold, or sell any securities of the Company, nor shall any part of it form the basis of or be relied upon in connection with any contract or investment decision. The financial results referred to herein are prepared in accordance with applicable Indian Accounting Standards and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and are subject to audit / limited review by the statutory auditors of the Company. Neither the Company nor its directors, officers, employees, or advisors accept any liability whatsoever for any loss or damage arising from the use of this information.

The Company undertakes no obligation to update any forward-looking statements or information contained herein to reflect subsequent events or circumstances, except as required under applicable law.

Explore further

Meet the people behind Aptus.

Read the profiles of our key managerial personnel and Board of Directors, or review our published financials.